Drug Trial Radar · NCT06914869
Drug-Drug Interaction Potential of Mavorixafor
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Feb 18, 2025
Primary completion
May 19, 2025
Study completion May 19, 2025
Sponsor
- Lead sponsor
- X4 PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Conditions
- Healthy Participants
Interventions
MavorixaforDrug
Mavorixafor will be administered per schedule specified in the arm description.
CarbamazepineDrug
Carbamazepine will be administered per schedule specified in the arm description.
EfavirenzDrug
Efavirenz will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With CarbamazepineTime frame: Predose up to 120 hours postdose on Days 1 and 18
- Cohort 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With CarbamazepineTime frame: Predose up to 120 hours postdose on Days 1 and 18
- Cohort 2: Cmax of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With EfavirenzTime frame: Predose up to 120 hours postdose on Days 1 and 18
- Cohort 2: AUC0-last of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With EfavirenzTime frame: Predose up to 120 hours postdose on Days 1 and 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International LLC
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.